Literature DB >> 11139109

High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery.

P Tassani1, N Augustin, A Barankay, S L Braun, F Zaccaria, J A Richter.   

Abstract

OBJECTIVE: To rule out the effect of high-dose aprotinin in respect to the balance of proinflammatory and anti-inflammatory mediators induced by cardiopulmonary bypass (CPB).
DESIGN: Randomized, double-blind, placebo-controlled study.
SETTING: University-affiliated cardiac center. PARTICIPANTS: Twenty patients scheduled for coronary artery bypass graft surgery.
INTERVENTIONS: In group A patients (n = 10), high-dose aprotinin was administered (2 x 106 KIU pre-CPB, 2 x 10(6) KIU in prime, 500,000 KIU/hr during CPB). In group C patients (n = 10), placebo was used instead. Proinflammatory interleukin (IL)-6, anti-inflammatory IL-1-receptor antagonist, and clinical parameters were measured 8 times perioperatively. The values are presented as mean +/- SEM.
MEASUREMENTS AND MAIN RESULTS: Four hours after CPB, IL-6 concentration reached the maximum value, being significantly lower in group A patients as compared with group C patients (615 +/- 62 pg/mL v 1,409 +/- 253 pg/mL; p = 0.019). On the first postoperative day, the concentration of IL-6 in group A patients remained lower (219 +/- 24 pg/mL v 526 +/- 123 pg/mL; p = 0.015). In contrast, IL-1-receptor antagonist concentration was higher in group A patients as compared with group C patients after CPB (13,857 +/- 4,264 pg/mL v 5,675 +/- 1,832 pg/mL; p = 0.03). Total postoperative blood loss was lower in group A patients as compared with group C patients (648 +/- 64 mL v 1,284 +/- 183 mL; p = 0.002).
CONCLUSIONS: High-dose aprotinin treatment reduced the inflammatory reaction and postoperative blood loss. The anti-inflammatory reaction was significantly enhanced in these patients, which suggests that the physiologic reaction of the organism to reduce the deleterious effects from CPB is more pronounced by using high-dose aprotinin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11139109     DOI: 10.1053/jcan.2000.18328

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  6 in total

1.  Comparative analysis of antifibrinolytic medications in pediatric heart surgery.

Authors:  Sara K Pasquali; Jennifer S Li; Xia He; Marshall L Jacobs; Sean M O'Brien; Matthew Hall; Robert D B Jaquiss; Karl F Welke; Eric D Peterson; Samir S Shah; Jeffrey P Jacobs
Journal:  J Thorac Cardiovasc Surg       Date:  2012-01-20       Impact factor: 5.209

2.  Suppressive effect of phosphodiesterase type 4 inhibition on systemic inflammatory responses after cardiopulmonary bypass.

Authors:  Masaki Hamamoto; Michiharu Suga; Yuzo Takahashi; Yukio Sato; Shuji Inamori; Toshikatsu Yagihara; Takeshi Nakatani; Soichiro Kitamura
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

Review 3.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

4.  Safety of aprotinin in congenital heart operations: results from a large multicenter database.

Authors:  Sara K Pasquali; Matthew Hall; Jennifer S Li; Eric D Peterson; James Jaggers; Andrew J Lodge; Jeffrey P Jacobs; Marshall L Jacobs; Samir S Shah
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

5.  Anti-inflammatory effect of aprotinin: a meta-analysis.

Authors:  Jeremiah R Brown; Andrew W J Toler; Robert S Kramer; R Clive Landis
Journal:  J Extra Corpor Technol       Date:  2009-06

6.  Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion.

Authors:  Matthew D McEvoy; Anna-Greta Taylor; Juozas A Zavadzkas; Ira M Mains; Rachael L Ford; Robert E Stroud; Laura B Jeffords; Christy U Beck; Scott T Reeves; Francis G Spinale
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.